Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 217

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 6
Chunk 217
---
                                                  
(5) Member of the Science and Development Committee.                                                                                                                                                                                                                                
(6) Chair of the Nomination Committee and the Remuneration Committee, member of the Science and Development Committee.                                                                                                                                                              
(7) Chair of the Science and Development Committee.                                                                                                                                                                                                                                 
(8) Member of the Audit Committee and the Remuneration Committee.                                                                                                                                                                                                                   
(9) Appointed by the Board by cooptation in 2024, subject to confirmation by the Shareholders' Meeting to be held on April 29, 2025.                                                                                                                                                
​
The address for the members of our Board of Directors is Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium.
Five out of nine of the members of the Board of Directors are independent under the Nasdaq Stock Market listing and US Securities Exchange Act requirements, and under Belgian law: Peter Guenter, Jérôme Contamine, Elisabeth Svanberg, Susanne Schaffert, and Simon Sturge. In 2024, the Board of Directors was therefore composed of a majority of independent Directors.
​
The following is the biographical information of the members of our Board of Directors (members per December 31, 2024):
Paul Stoffels1 joined Galapagos as Chief Executive Officer in April 2022, and is an Executive member and the Chairman of our Board of Directors since April 26, 2022. He also is a member of the Executive Committee at Galapagos. Prior to that, he was Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson where he set the company's wide innovation agenda and led its pharmaceutical R&D-pipeline, as well as the J&J external innovation agenda, and the J&J development corporation. Before that, he was worldwide Chairman of Pharmaceuticals of Johnson & Johnson which, under his leadership, significantly rejuvenated its product pipeline and adopted a transformational R&D-operating model, which resulted in the launch of 25 innovative medicines across the globe. Dr. Stoffels joined Johnson & Johnson in 2002, following the acquisition of Virco and Tibotec, where he was Chief Executive Officer and Chairman respectively, and where he led the development of several breakthrough medicines for the treatment of HIV. Dr. Stoffels also is a member of the Supervisory Board of Philips Healthcare in the Netherlands.

1 Stoffels IMC BV, permanently represented by Dr. Paul Stoffels
​

​
157

Peter